Each of the INDIVIDUAL result below - present this and early next week can make VLA be a billion take over target....VLA is worth more than that as it been proven to be effective in multi cancers target.
Combination of a novel oncolytic immunotherapeutic agent, CAVATAKTM (Coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and improves survival in an immune competent mouse melanoma model
Conclusion:
The significant anti-tumor activity mediated by the
combination of CAVATAK and checkpoint inhibitor antibodies
(anti-PD-1 and anti-CTLA-4) observed in the presented murine
melanoma model supports clinical evaluation of such an
immunotherapeutic combination treatment regime in patients
with advanced melanoma. Clinical evaluation of CAVATAK in
combination with immune checkpoint blockade in advanced
melanoma patients is currently underway.
Phase I/II STORM study: Intravenous delivery of a novel on colytic immunotherapy agent, CAVATAK, in advanced cancer patients.
Conclusion:
To date, multiple IV infusions in advanced cancer
patients have been generally well tolerated. Initial serum viral
load data indicate potential tumor-specific CVA21 replication
in some patients. Overall, the preliminary data offer an exciting
possibly that tumor targeting, infection and immune activation
mediated by IV CVA21 may lead to increases in anti-tumor
activity, particularly when in future used in combination with
immune checkpoint blockade
65 Poster Abstracts Oncolytic immunotherapy for the treatment of Non-Muscle Invasive Bladder Cancer using intravesical Coxsackievirus A21: Phase I/II CANON study.
Conclusion:
CVA21 is an oncolytic virus highly suited for
application in NMIBC. Modulation of ICAM-1 expression by very
low doses of mitomycin C facilitates increased virus entry into
tumour cells. The current phase I/II CANON study is currently
evaluating neoadjuvant CVA21 in this disease model.
Oncolytic Virotherapy for the Treatment of Non-Hodgkin Lymphoma
Conclusions:
CD54 expression in 5/6 NHL cell lines correlated
with susceptibility to CAVATAK and increased CD54 expression in
the LN-like environment potentiated susceptibility to CAVATAK
in some NHL cell lines at lower doses. Preliminary primary NHL
sample data shows that CD54 can be detected on B-Cells. These
results show promise for the use of CAVATAK to treat NHL as it is
effective against isolated NHL cell lines and those supported by
interactions within the tumour microenvironment.
VLA Price at posting:
80.0¢ Sentiment: Buy Disclosure: Held
